Mobile website
Archive > Volume 28 Issue 8 > 2021,28(8):818-823. DOI:10.3872/j.issn.1007-385X.2021.08.008 Prev Next
Clinical Research
Evaluation of the short-term efficacy and safety of bevacizumab combined with doxorubicin liposomes in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore the short-term efficacy and adverse reactions of bevacizumab combined with doxorubicin liposomes in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, as well as the survival of patients. Methods: A total of 76 patients with platinum-resistant recurrent epithelial ovarian cancer who were admitted to the 901 Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force from January 2018 to December 2019 were enrolled in this study. The patients were divided into a control group and an observation group with 38 cases in each by random number grouping method. The control group was given doxorubicin liposome single-agent chemotherapy for 4 cycles, while the observation group was given bevacizumab combined with doxorubicin liposome chemotherapy for 4 cycles. The short-term efficacy and adverse reactions of the two groups of patients after treatment were observed, and the changes in serum tumor markers HE4 (human epididymis protein 4) and CA125 (carbohydrate antigen 125) were detected. In addition, the patients were followed up for overall survival (OS) and disease progression[1]free survival (PFS). Results: The objective response rate (ORR) and disease control rate (DCR) of the control group were significantly lower than those of the observation group (ORR: 40.54% vs 69.44%; DCR: 67.57% vs 88.89%; all P<0.05). After treatment, the serum HE4 and CA125 levels of the observation group were (142.67±46.81) pmol/L and (31.79±11.65) U/L respectively, which were significantly lower than (219.33±75.67) pmol/L and (57.05±17.85) U/L of the control group (all P<0.05). There were no significant differences in adverse reactions such as gastrointestinal reactions, bone marrow suppression, liver and kidney damage, cardiotoxicity,allergic reactions, thromboembolism, and bleeding between the two groups (all P>0.05); the incidence of hypertension in the observation group was significantly higher than that in the control group (P<0.05), but it was controllable and tolerable. The median OS and median PFS of the patients in observation group were 17.2 months and 10.9 months respectively, which were significantly longer than the 14.1 months and 7.8 months of the control group (all P<0.05). Conclusion: For patients with platinum-resistant recurrent epithelial ovarian cancer, bevacizumab combined with doxorubicin liposomes has reliable short-term efficacy, good safety, and tolerable adverse reactions, which is worthy of clinical promotion.
Keywords:
Project Supported:
Project supported by the (Original) General Project of Nanjing Military Region (No. 15MS049)
Clc Number:
